Latest From Novocure Ltd.
The US Food and Drug Administration recently approved several first-of-a-kind diagnostics and a medical device, including a test kit for prosthetic joint infections, a Zika virus test and an electric field device to treat cancers.
The first reported analysis demonstrating a patient-level dose response with Novocure’s Tumor Treating Fields therapy is now published. The post-hoc analysis of the EF-14 trial showed higher doses of Tumor Treating Fields improved survival in newly diagnosed glioblastoma patients.
New results from the Phase II STELLAR trial shows Tumor Treating Fields therapy in conjunction with chemotherapy extends survival in previously untreated mesothelioma patients with no safety problems.
INNOVATE 3 is a phase 3 pivotal trial testing the efficacy of Novocure's Tumor Treating Fields therapy combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
- Radiofrequency Devices
- Therapeutic Areas
- Standen Ltd.
- Western Europe
- Parent & Subsidiaries
- Novocure Ltd.
- Senior Management
Asaf Danziger, CEO
Wilco Groenhuysen, CFO
Mike Ambrogi, COO
Eilon Kirson, MD, PhD, Head, R&D & CSO
Pritesh Shah, Chief Commercial Officer
- Contact Info
Phone: (972) 15 3475 6700
No. 4 The Forum, Grenville St.
Jersey , JE2 4UF
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.